Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | CASR | P41180 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146969 | 0.88 | LOXL2 (0.66) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL9675088 | 0.86 | LOXL2 (0.64) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL485998 | 0.84 | HPGD (0.64) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL17947424 | 0.84 | HPGD (0.64) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL5968633 | 0.84 | LOXL2 (0.67) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL20072395 | 0.84 | LOXL2 (0.62) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL12085830 | 0.84 | HPGD (0.64) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL21318392 | 0.84 | LOXL2 (0.62) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL21275558 | 0.84 | LOXL2 (0.62) | LOXL2HPGDCASRALOX5RAB9A | |
| SCHEMBL5968526 | 0.84 | LOXL2 (0.67) | LOXL2HPGDCASRALOX5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294821-A1 | CORROSION INHIBITION COMPOSITIONS AND METHODS OF USE IN SOUR ENVIRONMENTS | SAUDI ARABIAN OIL COMPANY (SA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| CN-115710199-B | Photooxidation reduction catalytic process | 深圳湾实验室坪山生物医药研发转化中心 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024129892-A2 | INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-08 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-7157462-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-01-02 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | LOXL2 4417/4885HPGD 3107/4885CASR 2251/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LOXL2 3514/4885HPGD 3809/4885CASR 2548/4885 |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | LOXL2 1187/4885HPGD 1712/4885CASR 2444/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | LOXL2 2764/4885HPGD 2642/4885CASR 207/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | LOXL2 3376/4885HPGD 1019/4885CASR 4316/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | LOXL2 2703/4885HPGD 632/4885CASR 4627/4885 |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | LOXL2 3102/4885HPGD 161/4885CASR 3697/4885 |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | LOXL2 2558/4885HPGD 2295/4885CASR 3407/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | LOXL2 2892/4885HPGD 1263/4885CASR 4356/4885 |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | TRPV1, OPRL1, CNR2 | LOXL2 1694/4885HPGD 861/4885CASR 1628/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LOXL2 1304/4885HPGD 4116/4885CASR 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.